You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IDH-2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Edmonton, Alberta, Canada
  • +1 more
Jan 31, 2023

Brain Tumor, Cancer Trial run by the National Cancer Institute (NCI) (Zotiraciclib)

Not yet recruiting
  • Brain Tumor
  • Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

Recruiting
  • Low-grade Glioma
  • +4 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 19, 2022

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Baltimore, Boston, Columbus (Enasidenib)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Baltimore, Maryland
  • +3 more
Aug 8, 2022

Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2023

Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

Recruiting
  • Recurrent IDH1/2 Mutated Glioma
  • Paris, France
    Pitie Salpetriere Hospital
Aug 29, 2022

Accelerated/Blast-phase Myeloproliferative Tumor, Chronic-phase Myelofibrosis, IDH2 Mutation Trial in Canada, United States

Recruiting
  • Accelerated/Blast-phase Myeloproliferative Neoplasm
  • +2 more
  • Scottsdale, Arizona
  • +10 more
May 9, 2022

Leukemia, Leukemia, Myeloid, Monocytic Leukemia Trial in Palo Alto (Enasidenib mesylat dose escalation)

Recruiting
  • Leukemia
  • +2 more
  • Enasidenib mesylat dose escalation
  • Palo Alto, California
    Stanford Cancer Institute
May 12, 2022

Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

Not yet recruiting
  • Diffuse Astrocytoma, IDH-Mutant
  • +20 more
  • NEO212 Oral Capsule
  • +8 more
  • (no location specified)
Sep 18, 2023

Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,

Active, not recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Baltimore, Maryland
  • +2 more
Feb 25, 2022

IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)

Recruiting
  • IDH Mutation
  • +4 more
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Glioma, Recurrence, Disease Attributes Trial (Vorasidenib)

Available
  • Glioma
  • +10 more
  • (no location specified)
Oct 19, 2022

Glioma, Gliomas, High Grade Glioma Trial run by the National Cancer Institute (NCI) (3T MRI scanner)

Recruiting
  • Glioma
  • +4 more
  • 3T MRI scanner
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Glioma Trial in United States (AG881)

Active, not recruiting
  • Glioma
  • Los Angeles, California
  • +8 more
May 16, 2022

Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

Not yet recruiting
  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic
  • (no location specified)
Oct 10, 2023

Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Houston (other,

Recruiting
  • Anaplastic Astrocytoma, IDH-Wildtype
  • +8 more
  • Quality-of-Life Assessment
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 8, 2022

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • (no location specified)
Jun 29, 2023

Glioma, IDH Mutation, Astrocytoma Trial in Philadelphia (Retifanlimab, All-trans retinoic acid)

Not yet recruiting
  • Glioma
  • +3 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jul 22, 2022

Glioblastoma, IDH-wildtype, Metformin, Malignancies Trial in Milan (Metformin)

Not yet recruiting
  • Glioblastoma, IDH-wildtype
  • +2 more
  • Milan, Italy
    Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Mil
Jun 26, 2023

IDH2 Mutations and Monitoring Molecular Residual Disease in AML

Enrolling by invitation
  • Acute Myeloid Leukemia
    • Taoyuan, State, Taiwan
      Chang Gung Memorial Hospital-Linkou
    Aug 4, 2021

    Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

    Recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • Decitabine and Cedazuridine
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 29, 2022

    Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme Trial in Cleveland (Eflornithine (Dose Level 1), Eflornithine

    Recruiting
    • Glioblastoma, IDH-wildtype
    • +4 more
    • Eflornithine (Dose Level 1)
    • +3 more
    • Cleveland, Ohio
      The Cleveland Clinic
    May 19, 2023

    Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Cobimetinib, Enasidenib Mesylate)

    Not yet recruiting
    • Recurrent Acute Myeloid Leukemia
    • Refractory Acute Myeloid Leukemia
    • Duarte, California
      City of Hope Medical Center
    Jun 28, 2022

    Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma Trial in United States (CYNK-001 systemic and Intra cavity

    Recruiting
    • Astrocytoma, Grade IV
    • +3 more
    • CYNK-001 systemic and Intra cavity administration
    • Duarte, California
    • +5 more
    Jan 20, 2023